LDS/Medical Tests/Morphine, Urine

Morphine, Urine

Morphine is the principal alkaloid of opium and is the prototype narcotic analgesic. As such, morphine is a constituent, often along with codeine, in poppy seeds. Morphine is rapidly absorbed after administration of a single dose and is a drug of preference for the patient who exhibits a variant CYP2D6 phenotype because it does not require metabolic activation. Morphine is administered by subcutaneous, intravenous, intramuscular and epidural injection of the sulfate salt. Morphine is used in continuous microinfusion devices as well. Oral formulations are available for immediate release or extended release. Morphine is rapidly metabolized to normorphine, morphine-6-glucuronide, morphine-3-glucuronide, and sulfate conjugates. Morphine-3-glucuronide is pharmacologically active and is may contribute significantly to the efficacy of chronic morphine therapy. Morphine is a metabolite of both of codeine, heroin, pholcodine, and ethylmorphine. The half-life of morphine is 1.3-6.7 hours.

More than 87% of an immediate release dose of morphine is eliminated within 72 hours, primarily as the morphine-3-glucuronide. Actual elimination depends on factors such as drug formulation dose, dose frequency, clinical status and pharmacokinetics of the individual patient.

Common side effects: respiratory depression, sedation, nausea, vomiting, dizziness, miosis, constipation, urinary retention. Morphine can also contribute to the following effects: euphoria, mental clouding, amnesia, hostility, irritability, pruritis, and vivid or disturbing dreams. Can be addictive. Overdose effects include respiratory collapse, seizure, coma, and possible death.

Morphine and metabolites can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.

  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A qualitative positive result indicates only the presence of Morphine and does not necessarily correlate with the extent of physiological and psychological effects, nor does it predict the dose that was taken or administered. Any result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method.

Therapeutic Level: 10-100 ng/ml
Toxic level: >200 ng/ml

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, or laboratory, whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report.

Many, including Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), Thin Layer Chromatography (TLC), or Immunoassay (IA). Immunoassays for opiates are generally sensitive but not specific to morphine. Targeted assays can distinguish between morphine and major metabolites. Many laboratories include a pre-analytical hydrolysis reaction to liberate the glucuronide and sulfate conjugates, which may improve detection.

Fresh urine specimen (random) collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 7-14 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* and *OPRM1* variants could guide drug and dose selection. Patients with poor or rapid metabolizer phenotypes for *CYP2D6* should not receive codeine because of the inherent risk of therapeutic failure or toxicity, respectively. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Foster City, CA: Biomedical Publications; 2011.
  • Levine B (ed). Miscellaneous Central Nervous System Depressants. In: Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press; 2013: 261-270.
  • Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.